Aduro Biotech data shows magnitude of STING activation by ADU-S100.
Aduro Biotech (ADRO) announced the publication of a peer-reviewed paper in Cell Reports authored by Aduro scientists and Novartis (NVS) collaborators as part of their ongoing research to study intratumoral stimulator of interferon genes, or STING, pathway activation as a potential therapeutic approach for the treatment of cancer. In this study, researchers determined an intratumoral dosing regimen of STING pathway activator, ADU-S100, optimized for adaptive immunity in mouse models. While high doses of ADU-S100 were effective at clearing injected tumors, researchers found that higher tumor ablative dosing regimens could compromise durable anti-tumor immunity. Lower immunogenic doses of ADU-S100 were shown to optimally elicit CD8+ T cell responses required for systemic and durable anti-tumor immunity, and were also found to be efficacious in combination with checkpoint inhibitor therapy.
|Printer friendly Cite/link Email Feedback|
|Date:||Dec 12, 2018|
|Previous Article:||Stifel would be buying Neurocrine on pullback after Tourette's failure surprise.|
|Next Article:||Accenture acquires selects professional service assets from Zafin.|